



- Company is not following good practice
- Company has made some progress
- Company is aligned with good practice
- No information

<b>Good Covid-19 Company Practices</b>	Covid-19 vaccine CureVac	Covid-19 vaccine Gamaleya Research Institute	Covid-19 vaccine Novavax	Covid-19 vaccine Sinopharm	Covid-19 vaccine Sinovac	Covid-19 Vaccine Pfizer	Covid-19 Vaccine Oxford / Astra Zeneca	Covid-19 Vaccine Moderna	Covid-19 Vaccine Johnson & Johnson	mab Casirivimab + Imdevimab	Bamlanivimab Ely Lilly	Remdesivir Gilead
A1. Publishes a global access plan for its product.	Red	Red	Red	Red	Red	Yellow	Red	Red	Red	Red	Yellow	Red
A2. Commits to comply with human rights standards in product development & marketing	Yellow	Red	Grey	Red	Red	Yellow	Red	Red	Yellow	Yellow	Red	Red
C1. The company commits to C-TAP or MPP	Red	Red	Red	Red	Red	Red	Red	Red	Red	Red	Red	Red
C2. Commits to not enforcing the exclusive rights of Covid-19 related patents.	Red	Red	Red	Red	Red	Red	Grey	Lightgreen	Red	Red	Red	Yellow
C3. Supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator.	Red	Yellow	Lightgreen	Yellow	Yellow	Yellow	Lightgreen	Yellow	Yellow	Grey	Grey	Grey
E1. The company makes the active ingredient available on reasonable grounds. [ therapeutics only]	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Red	Red	Red
E2. Commits to full technology transfer to other manufacturer	Yellow	Yellow	Yellow	Yellow	Yellow	Red	Yellow	Red	Yellow	Yellow	Red	Yellow
E3. Commits to non-profit or 'fair' pricing.	Red	Red	Red	Red	Red	Yellow	Lightgreen	Red	Lightgreen	Red	Yellow	Red
E4. Equitably distributes supplies globally. [vaccines only]	Red	Lightgreen	Yellow	Red	Red	Red	Yellow	Red	Red	Grey	Grey	Grey
E5. The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey
E6. Agrees to waive exclusive rights in regulatory test data [where applicable].	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey	Grey
T1. Publishes its R&D costs.	Red	Red	Yellow	Red	Yellow	Yellow	Lightgreen	Yellow	Lightgreen	Red	Yellow	Yellow
T2. Publishes its profit margin.	Yellow	Red	Red	Yellow	Yellow	Yellow	Lightgreen	Yellow	Lightgreen	Red	Yellow	Yellow
T3. The company publishes the average and/or marginal costs of production.	Red	Red	Red	Red	Red	Red	Red	Red	Red	Red	Red	Red
T4. Publishes its production capacity.	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Yellow
T5. The company publishes the public subsidies it received during product development and/or testing	Lightgreen	Yellow	Lightgreen	Red	Yellow	Lightgreen	Red	Yellow	Yellow	Red	Grey	Red
T6. Publishes the text of licensing agreements.	Yellow	Red	Red	Red	Red	Red	Yellow	Red	Red	Red	Red	Red
T7. Registers its clinical trials in public repositories.	Lightgreen	Lightgreen	Lightgreen	Yellow	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Lightgreen	Lightgreen